| P2093 | author name string | Sternberg CN | |
| P2860 | cites work | Tumor angiogenesis: therapeutic implications | Q27860595 |
| | Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha | Q28251443 |
| | Epidermal growth factor-related peptides and their receptors in human malignancies | Q28293442 |
| | Intermolecular association of the p185neu protein and EGF receptor modulates EGF receptor function | Q28678683 |
| | Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials | Q32034470 |
| | Gene therapy for osteoinduction | Q33725307 |
| | Antiandrogens in prostate cancer | Q33832646 |
| | Matrix metalloproteinases: biologic activity and clinical implications | Q33849967 |
| | Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells | Q33926746 |
| | The role of zoledronic acid in cancer: clinical studies in the treatment and prevention of bone metastases | Q33946299 |
| | Zoledronic acid in cancer patients with bone metastases: results of Phase I and II trials | Q34247913 |
| | Immunotherapy for prostate cancer | Q34328407 |
| | Growth factors and their receptors: new targets for prostate cancer therapy | Q34335662 |
| | Antisense therapy in oncology: new hope for an old idea? | Q34341868 |
| | Exisulind, a selective apoptotic antineoplastic drug | Q34481793 |
| | Systemic treatment and new developments in advanced prostate cancer | Q34558153 |
| | Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers | Q34608643 |
| | Inhibition of angiogenesis: treatment options for patients with metastatic prostate cancer | Q34722263 |
| | Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors | Q34787754 |
| | Chemosensitisation of malignant melanoma by BCL2 antisense therapy | Q40611574 |
| | Taxol in advanced, hormone-refractory carcinoma of the prostate. A phase II trial of the Eastern Cooperative Oncology Group | Q40711303 |
| | Weekly 1-hour infusion of paclitaxel. Clinical feasibility and efficacy in patients with hormone-refractory prostate carcinoma | Q40754620 |
| | Studies of the expression of epidermal growth factor receptor in human renal cell carcinoma: a comparison of immunohistochemical method versus ligand binding assay | Q40896653 |
| | Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer | Q41072693 |
| | Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system | Q41827081 |
| | Transcription-targeted gene therapy for androgen-independent prostate cancer | Q43169344 |
| | Docetaxel and exisulind in hormone-refractory prostate cancer | Q43784109 |
| | A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer | Q43784114 |
| | Preliminary phase I results of G3139 (bcl-2 antisense oligonucleotide) therapy in combination with docetaxel in hormone-refractory prostate cancer | Q43784117 |
| | Docetaxel, estramustine, plus trastuzumab in patients with metastatic androgen-independent prostate cancer | Q43784119 |
| | A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer | Q43801246 |
| | Combined modality radioimmunotherapy for human prostate cancer xenografts with taxanes and 90yttrium-DOTA-peptide-ChL6. | Q43833991 |
| | A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer | Q43931585 |
| | Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity | Q43982521 |
| | Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and leukemia group B 9480. | Q44102211 |
| | Human CD14+ leukocytes acquire the phenotype and function of antigen-presenting dendritic cells when cultured in GM-CSF and IL-4. | Q46309996 |
| | Phase II trial of GM-CSF in advanced prostate cancer. | Q51062836 |
| | Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. | Q53537244 |
| | Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. | Q53622998 |
| | Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer | Q60156367 |
| | Editorial: Hormone refractory metastatic prostate cancer | Q68181421 |
| | Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer | Q73690540 |
| | Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer | Q74593451 |
| | Phase II prostate cancer vaccine trial: report of a study involving 37 patients with disease recurrence following primary treatment | Q77377557 |
| | Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy | Q77839075 |
| P433 | issue | 2 | |
| P304 | page(s) | 136-146 | |
| P577 | publication date | 2003-01-01 | |
| P1433 | published in | European Journal of Cancer | Q332260 |
| P1476 | title | What's new in the treatment of advanced prostate cancer? | |
| P478 | volume | 39 | |